Intraocular Lens Cell Migration Inhibition System

Abstract

Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification of the eye.

Description

[0001]This application is a continuation-in-part of U.S. patent application Ser. No. 13 / 136,515, filed Aug. 2, 2011, which is a continuation-in-part of U.S. patent application Ser. No. 12 / 998,652, filed May 13, 2011, which is a United States National Stage of International Patent Cooperation Treaty Patent Application No. PCT / US2009 / 006195, filed Nov. 19, 2009, which claims the benefit of U.S. Provisional Patent Application No. 61 / 270,567, filed Jul. 10, 2009 and claims the benefit of U.S. Provisional Patent Application No. 61 / 199,674, filed Nov. 20, 2008, each hereby incorporated by reference herein.I. TECHNICAL FIELD[0002]Generally, an intraocular implant and methods for treating an ocular condition. In particular, an intraocular implant which implanted between an intraocular lens and the surface of the posterior capsule of the eye inhibits migration of residual lens epithelial cells after cataract surgery by providing structural barriers to reduce posterior capsule opacification o...

AI Technical Summary

Benefits of technology

[0012]Accordingly, a broad object of the invention can be to provide an intraocular implant having patterned surface elements which implanted between an intraocular lens and the surface

Problems solved by technology

However, there may be substantial problems with this procedure such as IOL damage, postoperative intraocular pressure spikes, vitreous floaters, cystoid macular edema, retinal detachment, and IOL subluxation, or the like.

Additionally, pediatric patients can be difficult to treat and a delay in treatment can lead to irreversible amblyopia.

Many underdeveloped countries do not have access to a Nd:YAG laser and the cost can be prohibitive.

Additionally, the majority of pharmacological agents tested in-vitro for inhibition of migration and proliferation of LECs are antimetabolites and antimitotics which have not been used clinically because of their toxic side effects.

Problems relating to incomplete seal of the lens capsule (45) resulting in leakage of potentially toxic chemicals into the anterior chamber (46) of the eye, rupture of the lens capsule (45) during manipulation of the irrigation device, difficulty in assessing kill of LECs within the lens capsule (45) and an increase in the duration of routine cataract surgery limit the usefulness of the irrigation device.

Another prominent problem with routine cataract surgery and other surgical procedures such as retinal surgery, cornea transplant surgery, glaucoma surgery, or the like, can be postoperative administration of antibiotics to prevent endophthalmitis.

However, there has yet to be a pr

Images